Interpace Biosciences Inc (Interpace Biosciences) formerly Interpace Diagnostics Group Inc, is a developer of molecular diagnostics tests. The company offers PancraGen, a DNA based molecular test that aids in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its pathfinder platform. It also provides ThyGenX and ThyraMIR that collectively assess the risk of benign or malignant thyroid nodules and minimizes unnecessary surgeries. Interpace Biosciences offers diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers. It also includes BarreGen and PathFinderTG which enables physicians to assess the risk of pregression to cancer. The company operates through its labs located in Pennsylvania, Pittsburgh, and New Haven, the US. Interpace Biosciences is headquartered in Parsippany, New Jersey, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note: Some sections may be missing if data is unavailable for the company
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Interpace Biosciences Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides a detailed description of products in development, technical specifications and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- Interpace Biosciences Inc Company Overview
- Interpace Biosciences Inc Company Snapshot
- Interpace Biosciences Inc Pipeline Products and Ongoing Clinical Trials Overview
- Interpace Biosciences Inc - Pipeline Analysis Overview
- Interpace Biosciences Inc - Key Facts
- Interpace Biosciences Inc - Major Products and Services
- Interpace Biosciences Inc Pipeline Products by Development Stage
- Interpace Biosciences Inc Ongoing Clinical Trials by Trial Status
- Interpace Biosciences Inc Pipeline Products Overview
- BarreGen
- BarreGen Product Overview
- BarreGen Clinical Trial
- Diagnostic Assay - Biliary Cancer
- Diagnostic Assay - Biliary Cancer Product Overview
- Diagnostic Test - Pancreatobiliary Cancer
- Diagnostic Test - Pancreatobiliary Cancer Product Overview
- Dyslexia Predisposition Test
- Dyslexia Predisposition Test Product Overview
- PancraGen - Das-1
- PancraGen - Das-1 Product Overview
- PancraMir
- PancraMir Product Overview
- PathFinderTG - Colon (Supernatant)
- PathFinderTG - Colon (Supernatant) Product Overview
- PathFinderTG - IBD
- PathFinderTG - IBD Product Overview
- PathFinderTG - Pancreas (Supernatant)
- PathFinderTG - Pancreas (Supernatant) Product Overview
- PathFinderTG - Ulcerative Colitis Supernatant
- PathFinderTG - Ulcerative Colitis Supernatant Product Overview
- PathFinderTG MvP Dx
- PathFinderTG MvP Dx Product Overview
- Serology Test - COVID-19
- Serology Test - COVID-19 Product Overview
- ThyraMIR
- ThyraMIR Product Overview
- ThyraMIR Clinical Trial
- Interpace Biosciences Inc - Key Competitors
- Interpace Biosciences Inc - Key Employees
- Interpace Biosciences Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Interpace Biosciences Inc, Recent Developments
- Aug 10, 2021: Interpace Biosciences Announces Second Quarter 2021 Financial and Business Results
- Mar 31, 2021: Interpace Biosciences Announces Full Year and Fourth Quarter 2020 Financial and Business Results
- Mar 09, 2021: Interpace Biosciences and XIFIN forge strategic partnership to improve financial performance
- Feb 04, 2021: Interpace Biosciences Announces CFO Leadership Transition
- Jan 20, 2021: Interpace Biosciences to Host Third Quarter 2020 Financial Results Conference Call on Thursday, January 21, 2021
- Jun 24, 2020: Interpace Biosciences to Host Conference Call and Webcast to Discuss First Quarter, 2020 Financial Results on Thursday June 25, 2020
- Mar 10, 2020: Interpace Diagnostics announces contract with BCBS of Massachusetts
- Mar 02, 2020: Interpace Biosciences announces acceptance of first paper demonstrating clinical performance of ThyGeNEXT with ThyraMIR
- Feb 24, 2020: Interpace announces extension of LabCorp agreement
- Feb 11, 2020: Interpace Biosciences announces another pricing improvement for its Thyroid Assay
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
List of Tables
- Interpace Biosciences Inc Pipeline Products and Ongoing Clinical Trials Overview
- Interpace Biosciences Inc Pipeline Products by Equipment Type
- Interpace Biosciences Inc Pipeline Products by Indication
- Interpace Biosciences Inc Ongoing Clinical Trials by Trial Status
- Interpace Biosciences Inc, Key Facts
- Interpace Biosciences Inc, Major Products and Services
- Interpace Biosciences Inc Number of Pipeline Products by Development Stage
- Interpace Biosciences Inc Pipeline Products Summary by Development Stage
- Interpace Biosciences Inc Ongoing Clinical Trials by Trial Status
- Interpace Biosciences Inc Ongoing Clinical Trials Summary
- BarreGen - Product Status
- BarreGen - Product Description
- BarreGen - A Collaborative Study to Evaluate the Use of BarreGen after Ablation of Dysplastic Barrett’s Esophagus
- Diagnostic Assay - Biliary Cancer - Product Status
- Diagnostic Assay - Biliary Cancer - Product Description
- Diagnostic Test - Pancreatobiliary Cancer - Product Status
- Diagnostic Test - Pancreatobiliary Cancer - Product Description
- Dyslexia Predisposition Test - Product Status
- Dyslexia Predisposition Test - Product Description
- PancraGen - Das-1 - Product Status
- PancraGen - Das-1 - Product Description
- PancraMir - Product Status
- PancraMir - Product Description
- PathFinderTG - Colon (Supernatant) - Product Status
- PathFinderTG - Colon (Supernatant) - Product Description
- PathFinderTG - IBD - Product Status
- PathFinderTG - IBD - Product Description
- PathFinderTG - Pancreas (Supernatant) - Product Status
- PathFinderTG - Pancreas (Supernatant) - Product Description
- PathFinderTG - Ulcerative Colitis Supernatant - Product Status
- PathFinderTG - Ulcerative Colitis Supernatant - Product Description
- PathFinderTG MvP Dx - Product Status
- PathFinderTG MvP Dx - Product Description
- Serology Test - COVID-19 - Product Status
- Serology Test - COVID-19 - Product Description
- ThyraMIR - Product Status
- ThyraMIR - Product Description
- ThyraMIR - Clinical Utility Combination Thyroid Test
- Interpace Biosciences Inc, Key Employees
- Interpace Biosciences Inc, Subsidiaries
- Glossary
List of Figures
- Interpace Biosciences Inc Pipeline Products by Equipment Type
- Interpace Biosciences Inc Pipeline Products by Development Stage
- Interpace Biosciences Inc Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Veracyte Inc
- Siemens Medical Solutions USA Inc
- NeoGenomics Inc
- GeneThera Inc
- Accelerate Diagnostics Inc
